In order to align production with GMP requirements, expand its product sales markets, implement a program for the development and launch of new medicinal products, and support the national import substitution initiative, PJSC "Kraspharma" has undertaken a full-scale technical modernization of its production facilities. Since 2014, the following production units have been established:

• Production of infusion solutions in polyolefin film bags (annual capacity: 14 million bags);
• Sterile filling of β-lactam antibiotics (annual capacity: 40 million vials);
• Production of solid non-sterile dosage forms;
• Generation of 8,000 liters/hour of Purified Water (PW), 3,450 liters/hour of Water for Injection (WFI), and 2,600 liters/hour of Pure Steam (PS);
• Production of injectable solutions in ampoules (annual capacity: 48 million ampoules), lyophilized products in ampoules (annual capacity: 1.016 million ampoules), and lyophilized products in vials (annual capacity: 400 thousand vials).

PJSC «Kraspharma» manufactures the following pharmaceutical products:

• The most in-demand parenteral antibiotics used in clinical practice, available in the forms of powders, lyophilizates, and infusion solutions; the antibiotic portfolio includes products for the treatment of infections caused by pathogens resistant to other antimicrobial agents;
• Antituberculosis chemotherapeutic agents in the forms of powders, lyophilizates, and infusion solutions;
• Medicines for the treatment of gastrointestinal diseases in the form of sterile powders and lyophilizates;
• Local anesthetics;
• Infusion solutions, including dextran-based blood substitutes, solutions affecting the water-electrolyte balance, fibrinolysis inhibitors, osmotic diuretic solutions, parenteral nutrition solutions, hydroxyethyl starch-based solutions, and detoxification agents.

The Company's business interests are not limited to the territory of the Russian Federation — PJSC "Kraspharma" products are in demand in 11 countries across Europe, Central, and South Asia.